A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior
Jermaine D. Jones, Shanna Babalonis, Ronald Marcus, Bradley Vince, Debra Kelsh, Michelle R. Lofwall, Heather Fraser, Blake Paterson, Suky Martinez, Diana M. Martinez, Edward V. Nunes, Sharon L. Walsh, Sandra D. Comer
Research output: Contribution to journal › Article › peer-review
16Scopus
citations
Fingerprint
Dive into the research topics of 'A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior'. Together they form a unique fingerprint.